# Comparison of SBRT and SIRT With Combination IO for Locally-advanced, Unresectable HCCs (BIIRTH)

> **NCT07293468** · PHASE2,PHASE3 · RECRUITING · sponsor: **Tuen Mun Hospital** · enrollment: 106 (estimated)

## Conditions studied

- Hepatocellular Carcinoma (HCC)

## Interventions

- **PROCEDURE:** Transarterial chemoembolization (TACE)
- **RADIATION:** Stereotactic Body Radiation Therapy (SBRT)
- **RADIATION:** SIRT Yttrium-90
- **DRUG:** Atezolizumab & Bevacizumab

## Key facts

- **NCT ID:** NCT07293468
- **Lead sponsor:** Tuen Mun Hospital
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-04-01
- **Primary completion:** 2034-03-31
- **Final completion:** 2034-12-31
- **Target enrollment:** 106 (ESTIMATED)
- **Last updated:** 2026-04-09

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07293468

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07293468, "Comparison of SBRT and SIRT With Combination IO for Locally-advanced, Unresectable HCCs (BIIRTH)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07293468. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*